OMS, 29 de septiembre 2014
Tabla
de contenidos
Regulatory
Matters
Azathioprine
...................................................................................
4
Docetaxel
.......................................................................................
4
Etonogestrel/ethinyl
estradiol slow release vaginal ring ................. 4
Lidocaine
Viscous
............................................................................
4
Methadone
(Oral)
.............................................................................
5
Ondansetron
....................................................................................
5
Renin-Angiotensin
system (RAS) acting agents ................................ 6
Serotonin
Antagonists
......................................................................
6
Strontium
ranelate
...........................................................................
7
Testosterone
products
......................................................................
7
Safety
of Medicines
Chlorhexidine
solution
......................................................................
9
Ferumoxytol
......................................................................................
9
Intravenous
dantrolene
.....................................................................
9
Ivabradine
.......................................................................................
10
Meningococcal
B Vaccine
................................................................. 10
Meso-2,
3-dimercaptosuccinic
acid................................................... 10
Ofatumumab.....................................................................................
11
Fentanyl
“patches”............................................................................
11
Vaccines
.......................................................................................
…..11
Voriconazole
......................................................................................
12
Zolpidem
......................................................................................
…..12
Signal
Agomelatine
and Hypotension
......................................................... 13
Dronedarone
and Polyneuropathy
.................................................... 19
Finasteride
and Convulsions
............................................................ 23
Roflumilast
and Pneumonia
............................................................. 29
Response
from Takeda and Forest Laboratories .................................
34
disponible
en
